Get the Stockscreener App
5.41
3.44%
0.18
Solid Biosciences Inc stock is traded at $5.41, with a volume of 394.67K.
It is up +3.44% in the last 24 hours and down -5.09% over the past month.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
See More
Previous Close:
$5.23
Open:
$5.26
24h Volume:
394.67K
Relative Volume:
1.41
Market Cap:
$216.15M
Revenue:
$14.79M
Net Income/Loss:
$-102.44M
P/E Ratio:
-0.8759
EPS:
-6.1766
Net Cash Flow:
$-91.73M
1W Performance:
+11.55%
1M Performance:
-5.09%
6M Performance:
-35.52%
1Y Performance:
+106.49%
1-Day Range:
$5.21
$5.62
1-Week Range:
$4.61
$5.62
52-Week Range:
$2.6301
$15.05
Solid Biosciences Inc Stock (SLDB) Company Profile
Name
Solid Biosciences Inc
Sector
Industry
Phone
617-337-4680
Address
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Compare SLDB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| SLDB | 5.41 | 216.15M | 14.79M | -102.44M | -91.73M | -6.1766 |
| VRTX | 450.97 | 116.38B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 82.09B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.14B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.25B | 3.30B | -501.07M | 1.03B | 11.54 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-15-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| May-31-24 | Resumed | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | William Blair | Outperform |
| Mar-15-24 | Initiated | Citigroup | Buy |
| Mar-14-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | Piper Sandler | Neutral |
| May-27-21 | Initiated | Jefferies | Buy |
| Mar-16-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-09-21 | Initiated | Barclays | Overweight |
| Jan-08-21 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jul-28-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-07-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-19 | Initiated | Evercore ISI | Outperform |
| Aug-29-19 | Downgrade | Citigroup | Neutral → Sell |
| Aug-19-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Aug-16-19 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| May-14-19 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-14-19 | Downgrade | Goldman | Neutral → Sell |
| Feb-08-19 | Upgrade | Citigroup | Sell → Neutral |
| Feb-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-06-18 | Initiated | Citigroup | Sell |
| Sep-06-18 | Initiated | Credit Suisse | Neutral |
View All
Solid Biosciences Inc Stock (SLDB) Latest News
Cantor Fitzgerald Brokers Reduce Earnings Estimates for SLDB - MarketBeat
Solid Biosciences Reports Increased Losses Amid R&D Focus - TipRanks
(SLDB) Investment Analysis - Stock Traders Daily
Litecoin Climbs 10% In Rally - Investing.com
Is Solid Biosciences (NASDAQ:SLDB) In A Good Position To Invest In Growth? - Simply Wall St
Perceptive Advisors LLC's Strategic Acquisition in Solid Bioscie - GuruFocus.com
Vestal Point Capital, LP Increases Stake in Solid Biosciences Inc. - GuruFocus.com
FY2024 Earnings Estimate for SLDB Issued By Chardan Capital - MarketBeat
Solid Biosciences to Present at the Jefferies London Healthcare Conference - GlobeNewswire
Solid Biosciences CEO to Present at Jefferies London Healthcare Conference | SLDB Stock News - StockTitan
Solid Biosciences' SWOT analysis: DMD therapy stock faces pivotal moment - Investing.com India
Solid Biosciences' SWOT analysis: DMD therapy stock faces pivotal moment By Investing.com - Investing.com UK
JPMorgan Chase & Co. Lowers Solid Biosciences (NASDAQ:SLDB) Price Target to $12.00 - MarketBeat
HC Wainwright Analysts Decrease Earnings Estimates for SLDB - MarketBeat
Leerink Partnrs Expects Lower Earnings for Solid Biosciences - MarketBeat
We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate - Yahoo Finance
Solid Biosciences Inc. (NASDAQ:SLDB) Receives $15.67 Consensus Target Price from Brokerages - MarketBeat
Solid Biosciences (NASDAQ:SLDB) Given Buy Rating at HC Wainwright - MarketBeat
Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates - The Manila Times
Solid Biosciences: SGT-003 Trial Shows Promise, $171M Cash Runway Despite Wider Q3 Loss | SLDB Stock News - StockTitan
Senhwa Biosciences announces first patient dosed in the Phase I/II study of Silmitasertib in children and young adults with relapsed refractory solid tumors. - PR Newswire
Where are the Opportunities in (SLDB) - Stock Traders Daily
Exosome Therapies on the Rise as 70+ Major Companies Driving Development in the Field | DelveInsight - The Malaysian Reserve
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Millennium Management LLC Reduces Stake in Solid Biosciences Inc - GuruFocus.com
Sow Good to Hold Third Quarter 2024 Conference Call on Thursday, November 14, 2024 at 10:00 a.m. ET - The Manila Times
Solid Biosciences to Participate at the Truist Securities BioPharma Symposium - GlobeNewswire
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Global Exosome Market to Surge at a Tremendous CAGR of ~20% by 2030 | DelveInsight - GlobeNewswire
Duchenne Muscular Dystrophy Therapeutics Market Trends, Growth Insights, and Forecasts 2033 - WhaTech
WRN inhibitor IDE-275 gains IND clearance for phase I study in MSI-high tumors - BioWorld Online
IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors - BioSpace
(SLDB) Proactive Strategies - Stock Traders Daily
Pillar Biosciences Receives CPT® Code for FDA Approved oncoReveal™ CDx Pan-Cancer Solid tumor IVD Kit - PR Newswire
Solid Biosciences CMO sells $18,999 in stock - Investing.com India
Solid Biosciences CMO sells $18,999 in stock By Investing.com - Investing.com Canada
Insider Selling: Solid Biosciences Inc. (NASDAQ:SLDB) Insider Sells 2,923 Shares of Stock - MarketBeat
Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences - Quantisnow
Seraxis gains IND clearance for islet replacement therapy - BioWorld Online
(SLDB) Trading Signals - Stock Traders Daily
Solid Biosciences Inc (SLDB) did well last session? - US Post News
Keeping an Eye on Solid Biosciences Inc (SLDB) After Insider Trading Activity - Knox Daily
Cubist Systematic Strategies LLC Sells 74,908 Shares of Huron Consulting Group Inc. (NASDAQ:HURN) - Defense World
Cubist Systematic Strategies LLC Has $368,000 Stock Position in Metropolitan Bank Holding Corp. (NYSE:MCB) - Defense World
Cubist Systematic Strategies LLC Makes New $378,000 Investment in Cryoport, Inc. (NASDAQ:CYRX) - Defense World
Great Lakes Dredge & Dock Co. (NASDAQ:GLDD) Shares Sold by Cubist Systematic Strategies LLC - Defense World
Cubist Systematic Strategies LLC Makes New $362,000 Investment in Anterix Inc. (NASDAQ:ATEX) - Defense World
Aegon Ltd. (NYSE:AEG) Stake Raised by Cubist Systematic Strategies LLC - Defense World
SG Americas Securities LLC Lowers Stock Position in Pool Co. (NASDAQ:POOL) - Defense World
Lindsay Co. (NYSE:LNN) Shares Sold by Cubist Systematic Strategies LLC - Defense World
Cubist Systematic Strategies LLC Sells 23,029 Shares of The St. Joe Company (NYSE:JOE) - Defense World
Solid Biosciences Inc Stock (SLDB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
2.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):